Bluebird Bio Inc. (NASDAQ:BLUE) had its price target upped by Leerink Swann from $67.00 to $80.00 in a research note issued to investors on Friday morning. Leerink Swann currently has an outperform rating on the stock.
Other analysts also recently issued reports about the stock. Piper Jaffray Cos. set a $95.00 price target on shares of Bluebird Bio and gave the stock a buy rating in a research note on Thursday, September 8th. Goldman Sachs Group Inc. reissued a buy rating and issued a $135.00 price target on shares of Bluebird Bio in a research note on Thursday, September 8th. Maxim Group reissued a buy rating and issued a $85.00 price target (down from $105.00) on shares of Bluebird Bio in a research note on Thursday, August 4th. BTIG Research reissued a buy rating and issued a $72.00 price target on shares of Bluebird Bio in a research note on Wednesday, June 29th. Finally, Jefferies Group reissued a buy rating and issued a $80.00 price target on shares of Bluebird Bio in a research note on Friday, July 8th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the company. Bluebird Bio presently has an average rating of Buy and a consensus price target of $91.60.
Shares of Bluebird Bio (NASDAQ:BLUE) opened at 54.90 on Friday. The stock has a 50 day moving average price of $63.92 and a 200 day moving average price of $51.26. The firm’s market capitalization is $2.04 billion. Bluebird Bio has a 1-year low of $35.37 and a 1-year high of $99.70.
Bluebird Bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The company earned $1.55 million during the quarter, compared to analysts’ expectations of $2.01 million. During the same quarter last year, the firm posted ($1.57) earnings per share. The firm’s revenue was down 68.6% on a year-over-year basis. Equities research analysts anticipate that Bluebird Bio will post ($6.19) earnings per share for the current fiscal year.
In other Bluebird Bio news, insider Eric Sullivan sold 416 shares of the company’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $67.00, for a total value of $27,872.00. Following the sale, the insider now owns 5,891 shares in the company, valued at $394,697. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 3.50% of the stock is currently owned by company insiders.
A number of large investors have recently made changes to their positions in the company. Wellington Management Group LLP acquired a new stake in shares of Bluebird Bio during the first quarter worth $51,095,000. BlackRock Fund Advisors boosted its stake in shares of Bluebird Bio by 80.0% in the second quarter. BlackRock Fund Advisors now owns 1,386,229 shares of the company’s stock worth $60,010,000 after buying an additional 616,095 shares during the period. State Street Corp boosted its stake in shares of Bluebird Bio by 41.4% in the second quarter. State Street Corp now owns 1,699,977 shares of the company’s stock worth $73,592,000 after buying an additional 498,041 shares during the period. RTW Investments LLC boosted its stake in shares of Bluebird Bio by 170.4% in the second quarter. RTW Investments LLC now owns 612,025 shares of the company’s stock worth $26,495,000 after buying an additional 385,654 shares during the period. Finally, Deerfield Management Co. acquired a new stake in shares of Bluebird Bio during the second quarter worth $14,636,000.
About Bluebird Bio
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.